Individualized Homeopathic Medicinal Products in the Treatment of Post-COVID-19 Conditions: A Double-Blind, Randomized, Placebo-Controlled, Feasibility Trial

• Published in: Journal of integrative and complementary medicine
• Main Authors: Rana, Abhijit, Bhattacharya, Pulakendu, Ganguly, Subhasish, Saha, Sangita, Naskar, Satyajit, Ghosh, Shubhamoy, Shaikh, Abdur Rahaman, Koley, Munmun, Saha, Subhranil, Mukherjee, Shyamal Kumar
• Format: Journal Article
• Language: English
• Published: United States 25.09.2024
• Subjects: randomized-controlled trial; post COVID-19 conditions; homeopathy; MYMOP-2; placebo
• ISSN: 2768-3613
• DOI: 10.1089/jicm.2024.0102

Evidence suggests that post-coronavirus disease 2019 (COVID-19) is associated with reduced health-related quality of life, and up to 80% of those infected with COVID-19 may experience these symptoms. The objective of the present study was to identify the effects of individualized homeopathic medicinal products (IHMPs) against placebos in postCOVID-19 conditions. Double-blind, randomized (1:1), two parallel arms, placebo-controlled, feasibility trial. D. N. De Homoeopathic Medical College & Hospital, Kolkata, West Bengal, India. Sixty participants with post-COVID-19 conditions. Group verum ( = 30; IHMPs plus concomitant care) versus group control ( = 30; placebos plus concomitant care). Feasibility issues; primary-post-COVID-19 symptoms checklist; secondary-Measure Yourself Medical Outcomes Profile version 2 (MYMOP-2); all of them were measured at baseline, and monthly intervals, up to 3 months. The intention-to-treat sample was analyzed; group differences were reported using descriptive statistics: means, 95% confidence intervals (CIs), and between group effect sizes (Cohen's ). Feasibility concerns showed promise; recruitment, retention, and attrition rates were 34.2%, 95%, and 5%, respectively. Group differences in both primary and secondary outcomes favored IHMPs against placebos: symptoms checklist score mean difference after 3 months: -4.2, 95% CI -4.9 to -3.4, = 2.854 and MYMOP-2 mean difference after 3 months: -2.2, 95% CI -2.8 to -1.7, = 2.082, respectively. (11.7%), (10%), (8.3%), and (8.3%) were the most frequently prescribed remedies. IHMPs produced better results than placebos in reducing symptoms checklist scores and MYMOP-2 scores in the treatment of post-COVID-19 conditions. Definitive trials are warranted to confirm the findings.